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Background: There is growing evidence of the protective role of dietary intake of flavonoids and lignans on cancer, but the
association with bladder cancer has not been thoroughly investigated in epidemiological studies. We evaluated the association
between dietary intakes of total and subclasses of flavonoids and lignans and risk of bladder cancer and its main morphological
type, urothelial cell carcinoma (UCC), within the European Prospective Investigation into Cancer and Nutrition (EPIC) study.
Methods: A cohort of 477 312 men and women mostly aged 35–70 years, were recruited in 10 European countries. At baseline,
dietary flavonoid and lignan intakes were estimated using centre-specific validated questionnaires and a food composition
database based on the Phenol-Explorer, the UK Food Standards Agency and the US Department of Agriculture databases.
Results: During an average of 11 years of follow-up, 1575 new cases of primary bladder cancer were identified, of which 1425 were
UCC (classified into aggressive (n¼ 430) and non-aggressive (n¼ 413) UCC). No association was found between total flavonoid
intake and bladder cancer risk. Among flavonoid subclasses, significant inverse associations with bladder cancer risk were found
for intakes of flavonol (hazard ratio comparing fifth with first quintile (HRQ5–Q1) 0.74, 95% confidence interval (CI): 0.61–0.91;
P-trend¼ 0.009) and lignans (HRQ5–Q1 0.78, 95% CI: 0.62–0.96; P-trend¼ 0.046). Similar results were observed for overall UCC and
aggressive UCC, but not for non-aggressive UCC.
Conclusions: Our study suggests an inverse association between the dietary intakes of flavonols and lignans and risk of bladder
cancer, particularly aggressive UCC.
Bladder cancer is the sixth most common cancer type and the
seventh most common cause of death from cancer in Europe
overall, although certain populations are highly affected (Ferlay
et al, 2010). Indeed, men are about three times more likely to
develop bladder cancer compared with women (Ferlay et al, 2010).
Moreover, it is predominantly a disease of high-income countries
and overall rates have remained relatively stable over the last
decades (Burger et al, 2013).
In 2007, a comprehensive review by the World Cancer Research
Fund and the American Institute for Cancer Research concluded
that established risk factors for bladder cancer include tobacco
consumption, infection with Schistosoma haematobium, and both
occupational and environmental exposures to carcinogens such as
aromatic amines and polycyclic aromatic hydrocarbons and
arsenic in drinking water. In contrast they showed that food,
nutrition and physical activity only had modest effects in the
development of bladder cancer (World Research Cancer Fund and
American Institute for Cancer Research, 2007). Since then,
investigations of the European Prospective Investigation into
Cancer and Nutrition (EPIC) cohort have found that fruit and
vegetable intake measured from dietary questionnaires was not
clearly related to bladder cancer (Buchner et al, 2009; Ros et al,
2012), although higher plasma carotenoids concentrations were
associated with lower incidence of bladder cancer (Ros et al, 2010);
suggesting that specific compounds in fruit and vegetables may
have protective associations with bladder cancer risk. In addition, a
recent study in the multiethnic cohort has suggested that intake of
fruit and vegetables and some related micronutrients such as
vitamins A, C, E and carotenoids were inversely associated with
bladder cancer risk only in women (Park et al, 2013).
One group of bioactive compounds in fruit and vegetables of
growing interest for chronic disease prevention is polyphenols
(basically flavonoids, phenolic acids and lignans), which have been
shown to have antioxidant, anti-inflammatory and anti-carcinogenic
effects in animals and in vitro studies (Yao et al, 2004; Xiao et al,
2011). The biological activity of flavonoids and lignans in the
prevention of bladder cancer is plausible considering that most of the
flavonoid and lignan metabolites are excreted through urine,
exposing the bladder lining to these metabolites (Manach et al, 2005).
To the best of our knowledge, only the Iowa Women’s Health
Study prospectively assessed the relationship between flavan-3-ol
monomer intake (a flavonoid subclass) and bladder cancer risk,
and found no association (Arts et al, 2002). Moreover, in a Spanish
case–control study, no associations were observed with some
individual flavonols and flavones (Garcia et al, 1999). Further
epidemiological studies in other large populations (including men)
and the assessment of the effect of the other flavonoid subclasses
are needed. Therefore, the aim of this study was to investigate the
association between the dietary intake of both total and subclasses
of flavonoids and lignans and bladder cancer risk in the EPIC
study, a large cohort with a high variability in the intake of these
compounds (Zamora-Ros et al, 2012, 2013).
MATERIALS AND METHODS
Study design. The EPIC is an on-going multicentre cohort study
designed to examine the association between diet, lifestyle and
environmental factors and cancer. The full rationale, methods and
design have been described previously (Riboli and Kaaks, 1997;
Riboli et al, 2002). Briefly, the EPIC study involves more than half a
million men and women from 23 centres in 10 European countries
(Denmark, France, Germany, Greece, Italy, the Netherlands, Nor-
way, Spain, Sweden and the United Kingdom). Participants, mostly
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aged between 35 and 70 years, were recruited from primarily the
general population during the period 1991–2000 (Riboli and Kaaks,
1997; Riboli et al, 2002). All participants gave written informed
consent, and the study was approved by the local ethics committees
in the participating countries and the ethical review board of the
International Agency for Research on Cancer (IARC).
Case ascertainment and follow-up. Follow-up for end point status
was mostly based on population cancer registries, except for France,
Germany and Greece, where a combination of methods including
health insurance records, cancer and pathology hospital registries,
and active follow-up were used. Mortality data were also collected
from registries at the regional or national level. The date of the last
complete follow-up (recorded in a central database at IARC) ranged
from December 2004 to June 2010, depending on the centre.
Bladder cancer cases were coded as C67 following the third
edition of the International Classification of Diseases for Oncology
(ICD-O-3). Bladder cancer cases with morphology codes 8980
(carcinosarcoma), 9590 (malignant lymphoma), 9671 (malignant
lymphoma, lymphoplasmacytic) and tumours with benign beha-
viours were censored at date of diagnosis. The analyses were also
done separately for the urothelial cell carcinomas (UCCs),
including urothelial cell papillomas and carcinomas (morphology
codes 812–813). The UCCs make up 490% of bladder tumours
(Allen et al, 2013). The UCC cases were separated into relatively
aggressive (high risk of progression) and non-aggressive (low risk
of progression) (Kiemeney et al, 2008), as described previously
(Ros et al, 2012). Briefly, aggressive UCC cases were defined as
stage T1 and higher or carcinoma in situ (CIS) or World Health
Organization (WHO) grade 3, whereas non-aggressive UCC cases
were defined as: stage Ta grade 1 or stage Ta grade 2. Tumour
aggressiveness was only classified for UCC cases diagnosed up until
2007, since these have been individually validated by pathology
reports, and the remaining tumours were censored at date of
diagnosis for stratified analyses.
Participants were excluded from the analyses if they had an
extreme energy intake and/or expenditure (participant in the top
or the bottom 1% of the distribution of the ratio of total energy
intake to energy requirement) (n¼ 9600) or if information on
dietary intake and lifestyle was incomplete (n¼ 6253). Further-
more, 28 289 participants were excluded because they had a
prevalent cancer at any site at baseline or were lost to follow-up. In
this present analysis, 477 312 subjects were included.
Dietary and lifestyle assessment. At recruitment, participant’s
dietary intake in the previous year was estimated using validated
and centre-specific questionnaires (Margetts and Pietinen, 1997;
Riboli et al, 2002). Dietary questionnaires in most of the centres
were quantitative, estimating portion sizes systematically. In
Denmark, Norway, Umeå (Sweden) and Naples (Italy), semiquan-
titative food-frequency questionnaires were administered. In
Malmo¨ (Sweden), a modified diet history method was used,
combining information from a 7-day diet record, a semiquantita-
tive questionnaire and a 1-h dietary interview. Energy (kcal day–1)
and ethanol (g day–1) intakes were estimated using the EPIC
Nutrient Database (Slimani et al, 2007). Lifestyle questionnaires
included questions on education, medical history, lifetime history
of consumption of tobacco and physical activity (Riboli et al, 2002;
Wareham et al, 2003). Height and weight at baseline were
measured in most of the centres, except for Oxford (UK), France
and Norway where anthropometric measures at baseline were self-
reported. BMI was calculated as weight in kilograms divided by
squared height in metres (kgm–2).
Dietary intake of total and subclasses of flavonoids (flavanols
(including flavan-3-ol monomers, proanthocyanidins, theaflavins),
anthocyanidins, flavonols, flavanones, flavones, and isoflavones)
and total lignans were estimated using our own database (Zamora-
Ros et al, 2012, 2013), which combines food composition data from
the USDA databases (U.S.Departament of Agriculture, 2004, 2007,
2008), Phenol-Explorer (Neveu et al, 2010) and the UK Food
Standards Agency database (Ward et al, 2010). Moreover, our food
composition database was expanded by using retention factors
(except for isoflavones and lignans) (Crozier et al, 1997;
U.S.Departament of Agriculture, 2008), developing recipes, and
estimating missing values based on similar foods (by botanical
family and plant part). Data on flavonoids and lignans are
expressed as aglycone equivalents, after conversing flavonoid
glycosides into aglycone contents using their respective molecular
weights. The final database contains 1877 food items (10% have
missing values) and includes raw foods, cooked foods and recipes.
Statistical analysis. Flavonoid and lignan intake was assessed by
the mean and its s.d., as well as the median and the 5th and 95th
centiles (P5th, P95th) because the data were skewed to the right.
The distribution of the population’s main characteristics according
to quintiles of total flavonoid intakes were examined using two-
sided w2 and Kruskal–Wallis tests, as appropriate. The relation-
ships between dietary intakes of flavonoids and lignans and bladder
cancer risk were assessed by estimating the hazard ratio (HR) and
its 95% confidence interval (CI) in Cox regression models. Tests
and graphs based on Schoenfeld residuals were used to assess the
proportional hazards assumption, which was satisfied. Total and
subclasses of flavonoids and lignans were categorised using cohort-
wide quintiles. Tests for linear trend were performed by assigning
the medians of each quintile as scores. Intakes were also analysed
continuously after a log2 transformation that indicates a reduction
of bladder cancer risk for doubling flavonoid and lignan intakes.
Hazard ratios were estimated using the following modelling
strategy; age was used as the underlying time scale, with entry
time defined as the participant’s age at baseline and exit time as age
at cancer diagnosis (for cases) or censoring (for at-risk partici-
pants), which was age at death or end of follow-up. Crude models
were stratified by centre, sex and age at baseline (1-year intervals).
Multivariable model 1 was additionally adjusted for total energy
intake (kcal day–1, continuous variable) and smoking status and
intensity (never, former quit o11 years, former quit 11–20 years,
former quit 420 years, current o15 cigarettes day–1, current
15–25 cigarettes day–1, current 425 cigarettes day–1, current occa-
sional smoker of pipe, cigarettes or other types of tobacco, current/
former smokers with unknown value of intensity or time since
cessation and not specified). Other potential confounders were
additionally adjusted for in multivariable model 2, such as BMI
(kgm–2), physical activity (inactive, moderately inactive, moder-
ately active, active and not specified), highest educational level
(none, primary school, technical/professional school, secondary
school, university or higher and not specified) and alcohol intake
(g day–1). Any of these variables did not change effect estimates
410%, and therefore in the results we only show the multivariable
model 1 because the results in both models were almost identical.
The interactions between sex, BMI status (o25; 25–29.9; X30 kg
m–2) or tobacco status (never, former and current smokers) and
total and subclasses of flavonoid and lignan intakes were tested
using likelihood ratio tests based on the models with and without
the interaction terms. Sensitivity analyses were performed after
exclusion of 181 cases who were diagnosed during the first 2 years
of follow-up. P-values o0.05 (two-tailed) were considered
significant. All analyses were conducted using SAS version 9.1
software (SAS Institute, Inc., Cary, NC, USA).
RESULTS
Among 477 312 (29.8% men) participants included in this study,
with a mean follow-up of 11.0 years, 1575 (70.3% men) incident
primary bladder cancer cases were diagnosed, of which 1425 were
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identified as UCC (including 430 aggressive, 413 non-aggressive
and 52 unknown tumour aggressiveness UCC cases, and 530
unclassified cases; Table 1). The distribution of total and subclasses
of flavonoid and lignan intakes and their main food sources is
shown in the Table 2. The median intake of total flavonoids and
total lignans were 332.4mg day–1 and 1.3mg day–1, respectively.
Descriptive characteristics of the population by quintiles of total
flavonoid intake are shown in Table 3. There was a slightly greater
percentage of men and higher age at recruitment in the fifth
quintile compared with the first one. In addition, participants in
the fifth quintile had the lowest BMI, reported higher total energy
and alcohol. Furthermore, participants in the top quintile tended to
smoke less, have a higher educational level and be more physically
active compared with those in the bottom quintile.
Statistically significant inverse associations were found in the
crude models between bladder cancer risk and the intake of total
flavonoids, flavanols, flavan-3-ol monomers, proanthocyanidins,
theaflavins, flavonols, flavones and lignans; although in multi-
variable models, only the intakes of flavonols (HRQ5–Q1 0.75, 95%
CI: 0.61–0.91; P-trend¼ 0.009) and lignans (HRQ5–Q1 0.78, 95%
CI: 0.62–0.96; P-trend¼ 0.042) maintained the significant inverse
association with bladder cancer risk (Table 4).
Similar relationships were observed for UCC (Table 4), where
only flavonol intake was inversely associated with UCC risk
(HRQ5–Q1 0.76, 95% CI: 0.62–0.94; P-trend¼ 0.022) and lignan
intake tended to be inversely related to UCC risk (HRQ5–Q1 0.79,
95% CI: 0.63–1.00; P-trend¼ 0.090) in the multivariable model.
According to tumour stage and grade, flavonol (HRQ5–Q1 0.64, 95%
CI: 0.44–0.95; P-trend¼ 0.020) and lignan (HRQ5–Q1 0.59, 95% CI:
0.39–0.89; P-trend¼ 0.035) intakes were inversely related to
aggressive UCC, but not to non-aggressive UCC (Table 4).
There was no evidence that the relation between total flavonoid
and lignan intake and bladder cancer was modified by sex (P for
interaction¼ 0.19 and 0.23) or BMI (P for interaction¼ 0.52 and
0.30). Although the interactions with tobacco consumption were
not significant for the intake of total flavonoids and lignans (P for
interaction¼ 0.47 and 0.90, respectively), separate analyses were
presented for smoking status because it is a major risk factor of
bladder cancer (Supplementary Table 1). Similar results were
observed between the intake of total and subclasses of flavonoids
and lignans and bladder cancer risk (and subtypes) in never and
current smokers.
In the sensitivity analysis, similar associations between
the intake of flavonols (HRQ5–Q1 0.69, 95% CI: 0.56–0.86;
P-trend¼ 0.004) and lignans (HRQ5–Q1 0.76, 95% CI: 0.60–0.97;
P-trend¼ 0.055) and incidence of overall bladder cancer were
observed after the exclusion of bladder cancer cases diagnosed
within the first 2 years of follow-up.
DISCUSSION
The results in this large cohort of participants from 10 Western
European countries suggest that higher dietary intakes of flavonols
and lignans may be associated with an approximately 25% lower
bladder cancer risk. These protective associations were also
observed for UCC, in particular the aggressive tumours. No
associations were observed with either total or other flavonoid
subclasses.
To the best of our knowledge, there is only one other
prospective epidemiological study on flavonoids and bladder
cancer, which reported no association between flavan-3-ol
monomers and bladder cancer risk in the Iowa Women’s Health
Study, a postmenopausal women cohort from the United States
(Arts et al, 2002). Our finding provides further evidence for the
absence of any strong association between flavan-3-ol monomers,
one of the most abundant flavonoid subclasses, primarily found in
tea, and bladder cancer risk in a cohort that contains more cancer
cases (1575 vs 103) and includes men, who are at greater risk of
developing bladder cancer (70.3% of bladder cases). Conversely to
our results, in a Spanish case–control study, no association with
some individual flavonols and flavones was observed, but the food
composition table used in this study was quite old and therefore,
very limited (Garcia et al, 1999). In relation to other cancers of the
urinary tract, intake of flavonols and particularly quercetin was
inversely associated with renal cell carcinoma risk in the Alpha-
Tocopherol Beta-Carotene Cancer Prevention Study (Wilson et al,
2009) and in an Italian case–control study (Bosetti et al, 2007), but
not total flavonoids. However, to our knowledge, there are no
studies assessing the relationship between lignan intake and risk of
urinary tract cancers.
A randomised controlled trial, with an intervention group that
followed a month long diet rich in flavonoids from a typical
Mediterranean diet and green tea, showed a strong correlation
between urinary phenolics and an anti-mutagenicity activity,
indicated by an inhibition effect of urinary extracts on Salmonella
typhimurium mutations induced by MeIQx (as model substrate for
cytochrome P4501A2) (Malaveille et al, 2004). From the same
Table 1. Distribution of participants and bladder cancer and UCC cases according to tumour aggressiveness during 11 years of follow-up in the 10
countries participating in the EPIC study
Country All Person-years Bladder cancer cases UCC cases Aggressive UCC Non-aggressive UCC
Denmark 55 016 601466 303 284 112 80
France 67 385 699360 31 24 13 6
Germany 48 583 480614 199 171 46 40
Greece 26 032 247711 45 25 5 6
Italy 44 541 500407 183 143 45 42
Norway 35 169 342279 24 24 8 2
Spain 40 002 482582 146 138 24 61
Sweden 48 684 638931 289 281 90 80
The Netherlands 36 505 431252 104 101 30 29
United Kingdom 75 395 838397 251 234 57 67
TOTAL 477 312 5 262998 1575 1425 430 413
Abbreviations: EPIC¼European Prospective Investigation into Cancer and Nutrition study; UCC¼urothelial cell carcinoma.
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Table 2. Dietary intake of flavonoids and lignans (in mgday–1) and their main food sources in the EPIC study
Mean S.d. Median Percentile 5 Percentile 95 Food sources
Total flavonoids 437.2 335.0 332.4 90.8 1137.7 Fruits (40%), tea (19%), wine (12%), fruit juices (6%)
Flavanols 355.3 309.2 248.9 58.9 1013.4 Tea (44%), fruit (29%), wine (9%), chocolates (4%)
Flavan-3-ols monomers 176.6 253.5 46.4 9.4 731.5 Tea (84%), fruits (6%), wine (3%), chocolates (2%)
Proanthocyanidins 172.8 123.9 148.3 41.2 388.2 Fruits (53%), wine (14%), chocolates (6%), tea (4%)
Theaflavins 5.8 9.8 0.4 0 27.2 Tea (100%)
Anthocyanidins 28.3 22.5 22.5 5.4 70.4 Fruits (52%), wine (21%), vegetables (8%), fruit juices (7%)
Flavonols 27.2 17.3 22.4 8 61.8 Tea (26%), vegetables (23%), fruits (13%), soups (12%)
Flavanones 21.9 22.8 15.7 1.7 64.8 Fruits (50%), fruit juices (41%), wine (5%), vegetables (1%)
Flavones 3.5 4.1 2.5 0.4 9.8 Herbal tea (30%), wine (18%), fruits (16%), vegetables (15%)
Isoflavones 1.5 4.9 0.5 0.1 4.4 Soya products (40%), cakes (18%), cereals (11%), coffee (8%)
Lignans 1.5 0.8 1.3 0.6 2.9 Vegetables (24%), fruits (17%), cereals (16%), tea (10%)
Abbreviation: EPIC¼European Prospective Investigation into Cancer and Nutrition study.
Table 3. Baseline characteristics of the participants in the EPIC study according to quintiles of total flavonoids intake
Total flavonoid intake
Characteristics
All
(n¼477312)
Q1
(n¼95462)
Q2
(n¼95 463)
Q3
(n¼95462)
Q4
(n¼95463)
Q5
(n¼95462) P-value
Median flavonoid intake (mgday–1) 332.4 123.9 225.4 332.4 514.6 933.4
Sex, men (%) 29.8 29.7 29.8 29.1 29.5 30.9 o0.001
Age at enrolment (years)a 51.2 (9.9) 50.9 (9.1) 51.2 (9.6) 50.9 (9.6) 51.3 (9.9) 51.8 (11.3) o0.001
BMI (kgm–2)a 25.4 (4.3) 25.7 (4.4) 25.8 (4.4) 25.6 (4.3) 25.3 (4.2) 24.8 (4.0) o0.001
Energy intake (kcal day–1)a 2074 (619) 1791 (545) 2010 (569) 2142 (598) 2211 (638) 2217 (635) o0.001
Alcohol intake (g day–1)a 11.9 (17.1) 7.5 (12.2) 10.6 (15.4) 12.4 (16.9) 14.5 (18.7) 14.7 (20.1) o0.001
Educational level (%) o0.001
No formal education 4.4 5.0 5.9 5.5 3.9 1.7
Primary school 25.6 33.4 29.2 26.3 23.0 16.1
Technical/professional school 22.3 27.2 22.1 19.0 20.0 23.1
Secondary school 20.4 18.3 20.0 22.8 22.4 18.6
University degree 23.8 15.0 21.1 24.3 26.9 31.6
Not specifiedb 3.5 1.1 1.7 2.1 3.8 8.9
Smoking status and intensity (%) o0.001
Never smoker 43.0 36.4 43.0 44.3 44.6 46.8
Current, o15 cigarretes day–1 11.6 17.0 12.7 11.1 9.4 7.8
Current, 15–25 cigarretes day–1 6.3 11.2 6.9 5.5 4.4 3.2
Current, 25 cigarretes day–1 1.8 2.9 2.3 1.8 1.3 0.8
Former, from p10 years 9.6 9.9 9.5 9.4 9.7 9.3
Former, from 11 to 20 years 8.2 6.8 7.7 8.1 9.0 9.2
Former, from 420 years 7.9 6.6 7.0 6.8 8.2 10.9
Current, pipe/cigar/occas 8.4 5.3 7.8 10.2 10.6 8.1
Current/former, missing 1.6 1.7 1.5 1.3 1.5 2.1
Not specifiedb 1.6 2.2 1.6 1.5 1.3 1.8
Physical activity (%) o0.001
Inactive 20.7 20.0 22.5 22.0 19.5 19.3
Moderately inactive 31.3 24.8 31.2 33.7 34.2 32.8
Moderately active 22.2 16.4 21.1 23.5 24.9 25.2
Active 17.0 12.4 15.4 16.9 19.3 20.9
Not specifiedb 8.8 26.4 9.8 3.9 2.1 1.8
Abbreviations: BMI¼body mass index; Current, pipe/cigar/occas¼ current occasional smoker of pipe, cigarettes or other types of tobacco; EPIC¼European Prospective Investigation into
Cancer and Nutrition study.
aMean (s.d.).
bNot specified: details of educational level, smoking or physical activity not known.
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study, an increase in flavonoid intake was associated with a
decrease in DNA adducts, suggesting that a diet rich in flavonoids
may reduce genotoxicity in the human urinary bladder (Talaska
et al, 2006).
Epidemiological studies have suggested that a Mediterranean
diet reduces the risk of cancers at different organ sites (World
Research Cancer Fund and American Institute for Cancer
Research, 2007); although, in a recent study in the EPIC cohort,
no significant association was observed between adherence to the
Mediterranean diet and risk of bladder cancer in the overall cohort
(Buckland et al, 2014). However, in current smokers, a protective
association was suggested. A high concentration of flavonoids and
other polyphenols has been found in fruits and vegetables, red
wine, and other elements of the Mediterranean diet (Perez-Jimenez
et al, 2010). Despite this, there is inconsistent evidence on the role
of total fruit and vegetable intakes measured by dietary
questionnaires on bladder cancer risk (Sacerdote et al, 2007;
Buchner et al, 2009; Ros et al, 2012; Park et al, 2013). However,
intake of some vegetables subgroups was inversely associated with
bladder cancer risk, such as root vegetables in previous EPIC
studies (Buchner et al, 2009), particularly in aggressive UCC (Ros
et al, 2012), and yellow-orange vegetables in the Multiethnic
Cohort study (Park et al, 2013). It is worth bearing in mind that
vegetables were the main food source of flavonols and lignans in
this study. In addition, plasma concentrations of carotenoids
(a nutritional biomarker of fruit and vegetable consumption and
which are not limited by measurement errors inherent in dietary
questionnaires) were inversely associated with bladder cancer risk
(Ros et al, 2010). Therefore, several authors suggested that
polyphenols and other antioxidant micronutrients may be, at least
in part, responsible for the protective effect of the Mediterranean
diet on health (Pelucchi et al, 2009; Giacosa et al, 2013).
A beverage that is not typical of the Mediterranean diet but has
been related to bladder cancer protection and is rich in flavonoids
is green tea (Wang et al, 2013). Green tea polyphenols have been
shown to inhibit nitrosamine-mediated carcinogenesis in in vitro
bladder models (Chung et al, 1993). Human studies have
confirmed that green tea polyphenols interfere with carcinogenesis
by reducing nitrosation and chromosome damage (Steele et al,
2000). Green tea is not widely consumed in Europe, and therefore
was not in this study. Black tea is one of the main food sources of
flavonols, but it is also the main source of other flavonoid
subclasses (such as flavan-3-ol monomers and theaflavins) that
were not related to bladder cancer in the present study. Therefore,
our results suggest that flavonoids from black tea are not related to
bladder carcinogenesis, as concluded by a previous meta-analysis
(Wang et al, 2013).
In general, flavonoids and lignans can have a protective effect on
bladder cancer through inhibition of phase I and induction of
phase II enzymes. This protection may arise because of multiple
mechanisms of action, further complexified by the synergistic
behaviour of several compounds (Russo et al, 2012). In fact, in
subjects with higher consumption of foods rich in flavonoids, a
general upregulation of DNA repair genes has been observed, and
an inverse correlation with gene expression levels, which may
suggest a flavonoid-mediated reduction of DNA damage (Guarrera
et al, 2007). However, other explanations are also plausible, three of
which are: (i) flavonoids interfere with DNA repair; (ii) flavonoids
can have a more complex interaction with DNA damage, not based
on repair induction; and (iii) flavonoids can interfere with the
induction/selection of chromosome instability or bulky DNA
adducts by carcinogens.
In particular, individual flavonols have reduced proliferation of
bladder cancer cells in in vitro models. Kaempferol (Xie et al, 2013)
and myricetin (Sun et al, 2012) induced apoptosis in a dose-
dependent manner by increasing the cleavage of caspase-3.
Moreover, myricetin reduced the migration of human bladder
cancer T24 cells and the phosphorylation of Akt and MMP-9
expression; whereas the phosphorylation of p38 MAPK was
enhanced (Sun et al, 2012). In addition, quercetin reduced cancer
progression by altering the extracellular catabolism of nucleotides
in T24 cells (Rockenbach et al, 2013). No data are available on the
effects of lignans upon bladder cancer cells.
In terms of our study limitations, first, changes in lifestyle could
not be taken into account as we only collected baseline
questionnaires of diet and other lifestyle variables. Second,
measurement error in collecting self-reported dietary intake is
inevitable, although centre-specific validated questionnaires (Riboli
and Kaaks, 1997; Riboli et al, 2002) were used. Furthermore,
flavonoid and lignan intakes are likely to be underestimated as the
flavonoid database was incomplete (although an extensive common
database was used) (Zamora-Ros et al, 2012, 2013) and herb/plant
supplement intakes were omitted in these analyses (up to 5% in
Denmark, the highest consumer country) (Skeie et al, 2009). This
misclassification is likely to be random and therefore any association
between intake and disease risk is likely underestimated. Nutritional
biomarkers could be used to reduce this exposure misclassification
(Zamora-Ros et al, 2014). Third, the association between dietary
flavonoids and lignans with bladder cancer risk may be susceptible
to confounding because high flavonoid and lignan intake reflects a
healthier lifestyle. In our models, we have adjusted for other
determinants of healthy lifestyle, however, possible residual
confounding, especially due to smoking, cannot be excluded.
Despite of that, similar risk estimates were observed in never and
current smokers. Finally, we realise that our study is prone to the
well-known drawback of multiple comparisons. The strengths of our
multicentre study include its prospective and population-based
design, detailed information on diet, large heterogeneity in flavonoid
and lignan intake and a large sample of bladder cancer cases, with
validated information on tumour aggressiveness.
In conclusion, this large prospective study conducted in 10
European countries suggests inverse associations between dietary
intakes of flavonols and lignans and risk of bladder cancer, in
particular aggressive tumours of UCC. No associations were
observed with either total or other flavonoid subclasses.
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